CoChat
Sign Up
Cited by 111

The DOI matches its Crossref record.

Safety of anti‐immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection

Cruz, A. A., Lima, F., Sarinho, E., Ayre, G., Martin, C., Fox, H., Cooper, P. J.·2007·Clinical & Experimental Allergy
DOI 10.1111/j.1365-2222.2007.02650.xPMC PMC1859973
Open this paper in CoChat — free account

Abstract

Summary: Background Although the role of immunoglobulin E (IgE) in immunity against helminth parasites is unclear, there is concern that therapeutic antibodies that neutralize IgE (anti‐IgE) may be unsafe in subjects at risk of helminth infection. Objective We conducted an exploratory study to investigate the safety of omalizumab (anti‐IgE) in subjects with allergic asthma and/or perennial allergic rhinitis at high risk of intestinal helminth infection. The primary safety outcome was risk of infections with intestinal helminths during anti‐IgE therapy. Methods A randomized, double‐blind, placebo‐controlled trial was conducted in 137 subjects (12–30 years) at high risk of geohelminth infection. All subjects received pre‐study anthelmintic treatment, followed by 52 weeks' treatment with omalizumab or placebo. Results Of the omalizumab subjects 50% (34/68) experienced at least one intestinal geohelminth infection compared with 41% (28/69) of placebo subjects [odds ratio (OR) 1.47, 95% confidence interval (CI) 0.74–2.95, one‐sided P= 0.14; OR (adjusted for study visit, baseline infection status, gender and age) 2.2 (0.94–5.15); one‐sided P =0.035], providing some evidence for a potential increased incidence of geohelminth infection in subjects receiving omalizumab. Omalizumab therapy was well tolerated, and did not appear to be associated with increased morbidity attributable to intestinal helminths as assessed by clinical and laboratory adverse events, maximal helminth infection intensities and additional anthelmintic requirements. Time to first infection (OR 1.30, 95% CI 0.79–2.15, one‐sided P =0.15) was similar between treatment groups. Infection severity and response to anthelmintics appeared to be unaffected by omalizumab therapy. Conclusions In this exploratory study of allergic subjects at high risk of helminth infections, omalizumab therapy appeared to be safe and well tolerated, but may be associated with a modest increase in the incidence of geohelminth infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2222.2007.02650.x

Cites

Statistics

Figures

Fig. 1 Flow chart for determining intestinal helminth infection status. Intestinal helminth infections were defined as new infections if helminth eggs were detected in a faeces sample following a previously negative sample, or there was an increase in infection intensity [eggs per gram (epg)] for the same species at least 4 weeks after appropriate anthelmintic treatment or an increase in infection intensity (epg) for the same parasite species compared with the previous sample. The start date of a new infection was defined as the date on which the positive sample was taken. The end of a helminth infection was defined as the date on which either (1) anthelmintic treatment was given to treat a specific helminth infection or (2) no eggs/larvae were detected and the investigator considered the infection resolved or (3) when anthelmintic treatment was administered at the end of the 52-week treatment period.
Fig. 1 Flow chart for determining intestinal helminth infection status. Intestinal helminth infections were defined as new infections if helminth eggs were detected in a faeces sample following a previously negative sample, or there was an increase in infection intensity [eggs per gram (epg)] for the same species at least 4 weeks after appropriate anthelmintic treatment or an increase in infection intensity (epg) for the same parasite species compared with the previous sample. The start date of a new infection was defined as the date on which the positive sample was taken. The end of a helminth infection was defined as the date on which either (1) anthelmintic treatment was given to treat a specific helminth infection or (2) no eggs/larvae were detected and the investigator considered the infection resolved or (3) when anthelmintic treatment was administered at the end of the 52-week treatment period.CC BY · PubMed Central
Fig. 2 Flow of subjects through the study.
Fig. 2 Flow of subjects through the study.CC BY · PubMed Central
Fig. 3 Kaplan–Meier plot of time to first detection of infection with intestinal helminth parasite during core and follow-up phases. These data include data for discontinued patients, so the number of patients infected in this analysis (36 vs. 29) differs slightly from the number of reported infections during the 52-week treatment period (34 vs. 28).
Fig. 3 Kaplan–Meier plot of time to first detection of infection with intestinal helminth parasite during core and follow-up phases. These data include data for discontinued patients, so the number of patients infected in this analysis (36 vs. 29) differs slightly from the number of reported infections during the 52-week treatment period (34 vs. 28).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 27

  1. 10.1038/nrmicro962 · DOI
  2. Bundy DAP, 2004, The global epidemiology of infectious diseases, 243
  3. Jarrett EE, 1982, Production and activities of IgE in helminth infection, Prog Allergy, 31, 178
  4. Cooper PJ, 2002, IgE and anti‐IgE therapy in asthma and allergic disease, lung biology in health and disease, 54
  5. 10.1111/j.0105-2896.2004.00192.x · DOI · Paper page
  6. 10.1128/CMR.14.4.689-703.2001 · DOI
  7. 10.1016/S1081-1206(10)62175-8 · DOI
  8. 10.1183/09031936.02.00278102 · DOI
  9. 10.1067/mai.2001.117880 · DOI
  10. 10.1111/j.1365-2222.2004.1916.x · DOI
  11. 10.1016/S1081-1206(10)62170-9 · DOI
  12. 10.1183/09031936.01.00092101 · DOI
  13. Vignola AM, 2004, Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis, SOLAR, 59, 709
  14. MacGlashan DW, 1997, Down‐regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti‐IgE antibody, J Immunol, 158, 1438, 10.4049/jimmunol.158.3.1438 · DOI
  15. 10.2165/00003495-199753050-00004 · DOI
  16. 10.1080/00034983.1957.11685790 · DOI
  17. 10.4269/ajtmh.2001.65.610 · DOI
  18. Belizario VY, 2003, A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp, Bull World Health Organ, 81, 35
  19. 10.1067/mai.2003.1348 · DOI
  20. 10.1164/rccm.200211-1320OC · DOI
  21. 10.1159/000237225 · DOI
  22. Butterworth AE, 1996, Immunity and morbidity in Schistosoma mansoni infection, quantitative aspects, 55, 109
  23. 10.1126/science.8009216 · DOI
  24. Bell RG., 1996, IgE, allergies and helminth parasites, a new perspective on an old conundrum, 74, 337
  25. Moqbel R, 1990, Parasites and allergy, evidence for a ‘cause and effect’ relationship, 20, 611
  26. Finkelman FD, 1997, Cytokine regulation of host defense against parasitic gastrointestinal nematodes, lessons from studies with rodent models, 15, 505
  27. 10.1128/CMR.17.1.208-217.2004 · DOI

Cited by

Sorted by citations

Metadata

Authors
Cruz, A. A., Lima, F., Sarinho, E., Ayre, G., Martin, C., Fox, H., & Cooper, P. J.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2007-01-23
Volume
37
Issue
2
Pages
197-207
ISSN
  • 0954-7894
  • 1365-2222
DOI
10.1111/j.1365-2222.2007.02650.x
PMC
PMC1859973
Cited by
111
References
0
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review